{"id":"https://openalex.org/W1908107144","doi":"https://doi.org/10.1158/1535-7163.mct-15-0455","title":"HSP90 Inhibitor\u2013SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors","display_name":"HSP90 Inhibitor\u2013SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors","publication_year":2015,"publication_date":"2015-08-13","ids":{"openalex":"https://openalex.org/W1908107144","doi":"https://doi.org/10.1158/1535-7163.mct-15-0455","mag":"1908107144","pmid":"https://pubmed.ncbi.nlm.nih.gov/26271675"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-15-0455","doi":"https://doi.org/10.1158/1535-7163.mct-15-0455","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-15-0455","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057196078","display_name":"David A. Proia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David A. Proia","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079778615","display_name":"Donald Lawrence Smith","orcid":"https://orcid.org/0000-0001-5450-2290","observed_orcids":["https://orcid.org/0000-0001-5450-2290"]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Donald L. Smith","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100342746","display_name":"Junyi Zhang","orcid":"https://orcid.org/0000-0002-0001-2971","observed_orcids":["https://orcid.org/0000-0002-0001-2971","https://orcid.org/0009-0003-4970-8210","https://orcid.org/0000-0002-4319-4285"]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Junyi Zhang","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036775501","display_name":"John-Paul Jimenez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John-Paul Jimenez","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110967092","display_name":"Jim Sang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jim Sang","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035598007","display_name":"Luisa Shin Ogawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Luisa Shin Ogawa","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088356631","display_name":"Manuel Sequeira","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Manuel Sequeira","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056912217","display_name":"Jaime Acquaviva","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jaime Acquaviva","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103351190","display_name":"Suqin He","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suqin He","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101793627","display_name":"Chaohua Zhang","orcid":"https://orcid.org/0000-0001-9331-1577","observed_orcids":["https://orcid.org/0000-0001-9331-1577"]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chaohua Zhang","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063852287","display_name":"Vladimir Khazak","orcid":"https://orcid.org/0009-0009-9768-4368","observed_orcids":["https://orcid.org/0009-0009-9768-4368"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vladimir Khazak","raw_affiliation_strings":["2NexusPharma Inc., Langhorne, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2NexusPharma Inc., Langhorne, Pennsylvania","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087332592","display_name":"Igor A. Astsaturov","orcid":"https://orcid.org/0000-0002-8613-1890","observed_orcids":["https://orcid.org/0000-0002-8613-1890"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Igor Astsaturov","raw_affiliation_strings":["3Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062079325","display_name":"Takayo Inoue","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Takayo Inoue","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036758613","display_name":"Noriaki Tatsuta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Noriaki Tatsuta","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112906227","display_name":"Sami Osman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sami Osman","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051935182","display_name":"Richard C. Bates","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard C. Bates","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022904857","display_name":"Dinesh Chimmanamada","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dinesh Chimmanamada","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102508194","display_name":"Weiwen Ying","orcid":"https://orcid.org/0000-0002-5879-3782","observed_orcids":["https://orcid.org/0000-0002-5879-3782"]},"institutions":[{"id":"https://openalex.org/I4210158135","display_name":"Synta Pharmaceuticals (United States)","ror":"https://ror.org/00rkhrg48","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158135"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Weiwen Ying","raw_affiliation_strings":["1Synta Pharmaceuticals Corp., Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Synta Pharmaceuticals Corp., Lexington, Massachusetts","institution_ids":["https://openalex.org/I4210158135"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.8076,"has_fulltext":false,"cited_by_count":35,"citation_normalized_percentile":{"value":0.68418072,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":98},"biblio":{"volume":"14","issue":"11","first_page":"2422","last_page":"2432"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.8026999831199646,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.8026999831199646,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10934","display_name":"Heat shock proteins research","score":0.10819999873638153,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.06129999831318855,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sn-38","display_name":"SN-38","score":0.875},{"id":"https://openalex.org/keywords/topoisomerase-i-inhibitor","display_name":"topoisomerase I inhibitor","score":0.8569999933242798},{"id":"https://openalex.org/keywords/targeted-drug-delivery","display_name":"targeted drug delivery","score":0.8629999756813049},{"id":"https://openalex.org/keywords/tumor-targeting","display_name":"tumor targeting","score":0.6000000238418579},{"id":"https://openalex.org/keywords/irinotecan-metabolite","display_name":"irinotecan metabolite","score":0.8299999833106995},{"id":"https://openalex.org/keywords/controlled-drug-release","display_name":"controlled drug release","score":0.5019999742507935},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.7889999747276306},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.625}],"concepts":[{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.7112472057342529},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6090805530548096},{"id":"https://openalex.org/C2779682216","wikidata":"https://www.wikidata.org/wiki/Q419964","display_name":"Camptothecin","level":2,"score":0.5853478908538818},{"id":"https://openalex.org/C2777560012","wikidata":"https://www.wikidata.org/wiki/Q5924361","display_name":"Hsp90 inhibitor","level":5,"score":0.509060800075531},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.4820455014705658},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.473904013633728},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4424183964729309},{"id":"https://openalex.org/C2780508388","wikidata":"https://www.wikidata.org/wiki/Q1750127","display_name":"SN-38","level":5,"score":0.4100358486175537},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.3992970883846283},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3989524245262146},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.358714759349823},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.358582466840744},{"id":"https://openalex.org/C2775932338","wikidata":"https://www.wikidata.org/wiki/Q24772687","display_name":"Hsp90","level":4,"score":0.3008127808570862},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.29341375827789307},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2848624885082245},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.23036134243011475},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1535053253173828},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08079174160957336},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C205260736","wikidata":"https://www.wikidata.org/wiki/Q418939","display_name":"Heat shock protein","level":3,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077146","descriptor_name":"Irinotecan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008813","descriptor_name":"Mice, Inbred ICR","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008856","descriptor_name":"Microscopy, Fluorescence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D012118","descriptor_name":"Resorcinols","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D012118","descriptor_name":"Resorcinols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D012118","descriptor_name":"Resorcinols","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D015153","descriptor_name":"Blotting, Western","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016513","descriptor_name":"Mice, SCID","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018841","descriptor_name":"HSP90 Heat-Shock Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018841","descriptor_name":"HSP90 Heat-Shock Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047368","descriptor_name":"Tumor Burden","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D059004","descriptor_name":"Topoisomerase I Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D059004","descriptor_name":"Topoisomerase I Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D059004","descriptor_name":"Topoisomerase I Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-15-0455","doi":"https://doi.org/10.1158/1535-7163.mct-15-0455","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-15-0455","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:26271675","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26271675","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":48,"referenced_works":["https://openalex.org/W1267625934","https://openalex.org/W1540606473","https://openalex.org/W1691930647","https://openalex.org/W1871308790","https://openalex.org/W1970036954","https://openalex.org/W1978925562","https://openalex.org/W1988219667","https://openalex.org/W1988533633","https://openalex.org/W1990918503","https://openalex.org/W1992370143","https://openalex.org/W1993122592","https://openalex.org/W1993485911","https://openalex.org/W1998863708","https://openalex.org/W2005100930","https://openalex.org/W2015820492","https://openalex.org/W2023493483","https://openalex.org/W2024873626","https://openalex.org/W2025584298","https://openalex.org/W2027333133","https://openalex.org/W2028978816","https://openalex.org/W2029243355","https://openalex.org/W2030177226","https://openalex.org/W2032535564","https://openalex.org/W2061742438","https://openalex.org/W2065406885","https://openalex.org/W2075805324","https://openalex.org/W2088062002","https://openalex.org/W2098070947","https://openalex.org/W2099758152","https://openalex.org/W2099808918","https://openalex.org/W2112055293","https://openalex.org/W2113523455","https://openalex.org/W2115527176","https://openalex.org/W2117487251","https://openalex.org/W2118546237","https://openalex.org/W2121020331","https://openalex.org/W2125921134","https://openalex.org/W2133198629","https://openalex.org/W2133554539","https://openalex.org/W2135073488","https://openalex.org/W2136313288","https://openalex.org/W2137132470","https://openalex.org/W2140472323","https://openalex.org/W2143892831","https://openalex.org/W2150244588","https://openalex.org/W2171883353","https://openalex.org/W6632349211","https://openalex.org/W6637180878"],"related_works":["https://openalex.org/W2340742775","https://openalex.org/W1554223811","https://openalex.org/W3022856870","https://openalex.org/W4367673880","https://openalex.org/W2336080272","https://openalex.org/W3033147329","https://openalex.org/W1542068046","https://openalex.org/W3154029256","https://openalex.org/W3030998442","https://openalex.org/W4251196751"],"abstract_inverted_index":{"The":[0],"clinical":[1],"benefits":[2],"of":[3,23,52,70,109,117,143,147,172],"chemotherapy":[4],"are":[5],"commonly":[6],"offset":[7],"by":[8,82,129],"insufficient":[9],"drug":[10,174],"exposures,":[11],"narrow":[12],"safety":[13],"margins,":[14],"and/or":[15],"systemic":[16],"toxicities.":[17],"Over":[18],"recent":[19],"decades,":[20],"a":[21,133,163,169,188],"number":[22],"conjugate-based":[24],"targeting":[25,51],"approaches":[26],"designed":[27],"to":[28,65,132,176],"overcome":[29],"these":[30],"limitations":[31],"have":[32],"been":[33,160],"explored.":[34],"Here,":[35],"we":[36],"report":[37],"on":[38],"an":[39,57,61],"innovative":[40],"strategy":[41],"that":[42,59,77,99,167],"utilizes":[43],"HSP90":[44,62,79,101],"inhibitor-drug":[45],"conjugates":[46],"(HDC)":[47],"for":[48,89,106,192],"directed":[49],"tumor":[50,93,122],"chemotherapeutic":[53],"agents.":[54],"STA-12-8666":[55,130,158,186],"is":[56],"HDC":[58,165],"comprises":[60],"inhibitor":[63,84,102],"fused":[64],"SN-38,":[66],"the":[67,83,100,121],"active":[68,118],"metabolite":[69],"irinotecan.":[71],"Mechanistic":[72],"analyses":[73],"in":[74,149],"vitro":[75],"established":[76],"high-affinity":[78],"binding":[80],"conferred":[81],"backbone":[85],"could":[86],"be":[87],"exploited":[88],"conjugate":[90],"accumulation":[91],"within":[92,120],"cells.":[94],"In":[95],"vivo":[96],"modeling":[97],"showed":[98],"moiety":[103],"was":[104],"required":[105],"selective":[107],"retention":[108],"STA-12-8666,":[110],"and":[111,140,145,153,179],"this":[112],"enrichment":[113],"promoted":[114],"extended":[115],"release":[116,128],"SN-38":[119],"compartment.":[123],"Indeed,":[124],"controlled":[125],"intratumoral":[126],"payload":[127],"contributed":[131],"broad":[134],"therapeutic":[135],"window,":[136],"sustained":[137,180],"biomarker":[138],"activity,":[139],"remarkable":[141],"degree":[142],"efficacy":[144],"durability":[146],"response":[148],"multiple":[150],"cell":[151],"line":[152],"patient-derived":[154],"xenograft":[155],"models.":[156],"Overall,":[157],"has":[159],"developed":[161],"as":[162,187,194],"unique":[164],"agent":[166],"employs":[168],"distinct":[170],"mechanism":[171],"targeted":[173],"delivery":[175],"achieve":[177],"potent":[178],"antitumor":[181],"effects.":[182],"These":[183],"findings":[184],"identify":[185],"promising":[189],"new":[190],"candidate":[191],"evaluation":[193],"novel":[195],"anticancer":[196],"therapeutic.":[197]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":5},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}